Prevalence and determinants of lymphedema in newly diagnosed Nigerian breast cancer patients using bioimpedance estimations.
bioimpedance
breast
cancer
lymphedema
Journal
Ecancermedicalscience
ISSN: 1754-6605
Titre abrégé: Ecancermedicalscience
Pays: England
ID NLM: 101392236
Informations de publication
Date de publication:
2023
2023
Historique:
received:
10
12
2022
medline:
28
4
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
epublish
Résumé
Breast cancer-related lymphedema (BCRL) is common and has significant impact on quality of life. Very little is known about BCRL in sub-Saharan Africa. Generally, BCRL has been mostly evaluated post treatment, with very limited data on the prevalence of pre-treatment BCRL at baseline. This study presents the prevalence and clinical associations of lymphedema among newly diagnosed, treatment-naive breast cancer patients in a Nigerian cohort using bioimpedance estimations. Consecutively consenting, newly diagnosed, treatment-naive breast cancer patients were assessed for upper limb lymphedema using bioimpedance measurements of the extracellular fluid and the single-frequency bioelectrical impedance analysis value at 5 kHz. Patients were classified as having lymphedema if there was >10% difference in arm measurements or if the ratios of the arm measurements were >3 SD above a normative mean generated from representative controls. Regression analysis was performed to determine clinical variables associated with lymphedema. There were 154 breast cancer patients with a median age of 47 (40.0-56.8) years and a body mass index of 27 (23.5-30.9) kg/m The predominance of locally advanced disease in the Nigerian setting is associated with high pre-treatment lymphedema rates. This may set the stage for higher rates in the post-operative setting. Management of lymphedema should be incorporated into the treatment planning.
Sections du résumé
Background
UNASSIGNED
Breast cancer-related lymphedema (BCRL) is common and has significant impact on quality of life. Very little is known about BCRL in sub-Saharan Africa. Generally, BCRL has been mostly evaluated post treatment, with very limited data on the prevalence of pre-treatment BCRL at baseline. This study presents the prevalence and clinical associations of lymphedema among newly diagnosed, treatment-naive breast cancer patients in a Nigerian cohort using bioimpedance estimations.
Methods
UNASSIGNED
Consecutively consenting, newly diagnosed, treatment-naive breast cancer patients were assessed for upper limb lymphedema using bioimpedance measurements of the extracellular fluid and the single-frequency bioelectrical impedance analysis value at 5 kHz. Patients were classified as having lymphedema if there was >10% difference in arm measurements or if the ratios of the arm measurements were >3 SD above a normative mean generated from representative controls. Regression analysis was performed to determine clinical variables associated with lymphedema.
Results
UNASSIGNED
There were 154 breast cancer patients with a median age of 47 (40.0-56.8) years and a body mass index of 27 (23.5-30.9) kg/m
Conclusion
UNASSIGNED
The predominance of locally advanced disease in the Nigerian setting is associated with high pre-treatment lymphedema rates. This may set the stage for higher rates in the post-operative setting. Management of lymphedema should be incorporated into the treatment planning.
Identifiants
pubmed: 37113722
doi: 10.3332/ecancer.2023.1506
pii: can-17-1506
pmc: PMC10129379
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1506Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© the authors; licensee ecancermedicalscience.
Déclaration de conflit d'intérêts
The authors have no relevant financial or non-financial conflicts of interest.
Références
Ann Rehabil Med. 2011 Oct;35(5):687-93
pubmed: 22506192
Breast Cancer Res Treat. 2015 May;151(1):121-9
pubmed: 25850535
Anticancer Res. 2021 Jul;41(7):3233-3246
pubmed: 34230117
Lymphat Res Biol. 2009;7(2):81-5
pubmed: 19522677
Lymphology. 2001 Mar;34(1):2-11
pubmed: 11307661
Ecancermedicalscience. 2020 Aug 05;14:1084
pubmed: 32863878
BMC Cancer. 2019 Jul 8;19(1):669
pubmed: 31286884
Int J Cancer. 2021 Jun 15;148(12):2906-2914
pubmed: 33506499
Am J Surg. 2003 Nov;186(5):509-13
pubmed: 14599616
Support Care Cancer. 2011 May;19(5):703-10
pubmed: 20467755
Niger Med J. 2018 Nov-Dec;59(6):74-79
pubmed: 31423046
Eur J Clin Nutr. 2013 Jan;67 Suppl 1:S79-85
pubmed: 23299875
Int J Med Sci. 2021 Jun 11;18(13):2990-2996
pubmed: 34220327
JAMA Surg. 2020 Jun 1;155(6):513-519
pubmed: 32347903
Am J Surg. 2004 Jan;187(1):69-72
pubmed: 14706589
Breast Cancer Res Treat. 2016 Jun;157(2):229-240
pubmed: 27154787
Breast Cancer Res Treat. 2005 Feb;89(3):221-6
pubmed: 15754119
J Oncol Pract. 2019 May;15(5):255-262
pubmed: 31009281
Asian Pac J Cancer Prev. ;17(11):4875-4883
pubmed: 28030915
Oncol Lett. 2020 Mar;19(3):2085-2096
pubmed: 32194706
World J Clin Oncol. 2014 Aug 10;5(3):241-7
pubmed: 25114841
Ann Plast Surg. 2007 May;58(5):541-3
pubmed: 17452840